Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Weigao Puri Pharmaceutical Packaging for an assessed value of 8.511 billion yuan, marking a significant asset restructuring and expanding its business into pharmaceutical packaging [2] Group 1: Acquisition Details - The acquisition will be fully paid through the issuance of shares, with Weigao Co. and its concerted parties increasing their stake in Weigao Blood Purification to 84.36%, maintaining absolute control [2] - Weigao Puri, established in 2018, specializes in pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] Group 2: Financial Performance - As of June 30, 2025, Weigao Puri reported total assets of 3.425 billion yuan, total liabilities of 730 million yuan, and equity of 2.695 billion yuan, with a revenue of 939 million yuan and a net profit of 327 million yuan in the first half of 2025, indicating strong profitability [2] Group 3: Market Position - Weigao Puri has broken the overseas technology monopoly and holds a leading position in the domestic pre-filled product market, with over 50% market share from 2022 to 2024, ranking first domestically and among the top five internationally [3] Group 4: Strategic Rationale - The acquisition aims to diversify business operations and achieve technological synergy, allowing Weigao Blood Purification to leverage Weigao Puri's expertise in pharmaceutical packaging to expand its product line and reduce risks associated with a single business area [4] - The growing biopharmaceutical industry in China, projected to reach 534.8 billion yuan in 2024 and 1.13 trillion yuan by 2032, presents significant opportunities for both pharmaceutical packaging and upstream biopharmaceutical materials [4]

Group 1 - The company Shandong Weigao Blood Purification Products Co., Ltd. has received approval for its initial public offering (IPO) of A-shares and will be listed on the main board [1][2] - The total number of shares to be issued is 41,139,407 shares, with an initial strategic placement of 4,113,940 shares, accounting for 10% of the total issuance [2] - The final strategic placement amount is 1,772,075 shares, approximately 4.31% of the total issuance, leading to a total of 28,259,832 shares available for offline and online distribution [2][3] Group 2 - The IPO price is set at 26.50 yuan per share, with the initial issuance of 11,107,500 shares scheduled for May 8, 2025 [2][3] - The online subscription received an oversubscription rate of approximately 7,518.35 times, prompting the activation of a mechanism to adjust the allocation between offline and online investors [2][3] - After the adjustment, the final allocation is 12,512,832 shares for offline investors (31.78%) and 26,854,500 shares for online investors (68.22%) [3] Group 3 - The final online winning rate for investors is approximately 0.03215719% [3] - Investors are required to fulfill their payment obligations by May 12, 2025, and must ensure sufficient funds in their accounts [4] - The company has established a lock-up period of 6 months for 10% of the shares allocated to strategic placement investors, while 90% of the shares will be tradable immediately after listing [5][6] Group 4 - The strategic placement includes a special asset management plan for the company's senior management and core employees, managed by Huatai Securities [6][7] - The total amount of funds committed by strategic placement investors has been received in full by the underwriter [7] - The online lottery for share allocation was conducted on May 9, 2025, with a total of 53,709 winning numbers announced [8][9]